XTalks

DECEMBER 4, 2024

Jupiter Neurosciences, a clinical-stage pharma company specializing in neuroinflammation, made its public market debut with an initial public offering (IPO) on the Nasdaq Capital Market under the symbol “JUNS.” ” The company priced 2,750,000 shares of common stock at $4.00

Bioavailability 111

Bioavailability Genetic Disease Marketing RNA 111

pharmaphorum

JANUARY 10, 2022

The pandemic brought about an interesting phenomenon for the pharmaceutical industry: there is a much greater awareness of both individual companies within the industry and their individual treatments. Prior to the pandemic, biotech had a market cap of around $6.5bn whereas, at present, it is now valued at approximately $144bn.

RNA 111

RNA Vaccination Vaccine Pharma Companies 111

XTalks

DECEMBER 22, 2021

The RNA Revolution: From mRNA Vaccines to RNA Editing. The age of RNA is officially here, and it’s here to stay as more than a passing life science trend. RNA technology is not new nor has its potential been surprising. RNA in the Making. So why did this perceived RNA ‘revolution’ take so long?

Life Science 98

Life Science RNA Vaccination Vaccine 98

XTalks

JANUARY 3, 2025

XTALKS WEBINAR: Environmental Sustainability and the Supply of Medicines for Clinical Trials Live and On-Demand: Thursday, January 16, 2025, at 10am EST (4pm CET/EU-Central) Register for this free webinar to learn how major pharma companies are working towards environmental sustainability and reducing their environmental impact.

FDA Approval 59

FDA Approval Drugs Clinical Trials Clinical Trials 59

XTalks

DECEMBER 13, 2023

These companies were identified through The Americas’ Fastest-Growing Companies 2023 list by the Financial Times. The company boasts an expansive portfolio of assets that grant rights to future potential royalty and milestone payments.

Genetics 111

Genetics Vaccination Vaccine DNA 111

XTalks

JANUARY 6, 2025

From leveraging artificial intelligence (AI) to streamline diagnostics and treatments to exploring the untapped potential of RNA-based therapeutics, biotechnology is shaping the future of healthcare and beyond. As of January 31, 2024, approximately 131 unique RNA-based therapies are in clinical development across various therapeutic areas.

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111